Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm
5.3.2026 09:55:07 EET | Grünenthal Group | Press release
Aachen, Germany & Yeoju, South Korea, 5 March 2026 – Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will have the exclusive South Korean rights to Qutenza®, a topical, non-systemic, non-opioid patch treatment. In Europe, the product is indicated for the management of peripheral neuropathic pain.
Under the agreement, BCWP will be responsible for obtaining marketing authorisation for Qutenza® in South Korea. Upon approval, the company will market and distribute the product. Grünenthal will receive an upfront payment in addition to regulatory and sales-related milestone payments.
“We are executing on a dedicated strategy to bring Qutenza® into the Asia-Pacific region to facilitate greater access to non-opioid treatment options for people living with pain and expand the brand's global footprint,” says Jan Adams, Chief Commercial Officer (CCO) at Grünenthal. “With BCWP, we have a strong speciality care partner in South Korea, a major market in the Asia-Pacific region, and we are pleased to expand our existing partnership to further progress towards our vision of a World Free of Pain.”
“Expanding access to innovative, non-opioid treatment options for patients with neuropathic pain is central to our mission of ‘Commit to a Better Future for Patients’,” says Steve Hong, CEO of BCWorld Pharm. “Our partnership with Grünenthal enables us to introduce Qutenza® to South Korea while further diversifying and strengthening our pain management portfolio.”
Grünenthal acquired the global rights to Qutenza® in 2018 as part of its M&A-driven growth strategy. Since 2017, Grünenthal has closed successful acquisitions with a total expected deal value of more than €2.3 billion, diversifying its portfolio, enhancing its profitability, and driving business growth. Grünenthal continues to expand the footprint of the acquired brands and to create synergies throughout Grünenthal's infrastructure, including manufacturing, supply, logistics, and commercial activities.
Keywords
Contacts
Grünenthal
Maren Thurow
Head Global Communication
Phone: +44 7917 196855
Maren.Thurow@grunenthal.com
BCWorld Pharm
Jin Ho Lee
Manager, Strategic Planning
Phone: +82 31 5178 3442
jinho.lee@bcwp.co.kr
Links
About Qutenza®
In Europe, Qutenza is indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain. For further information, please visit www.grunenthalhealth.com.
Qutenza (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important US safety information is available at www.qutenza.com.
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2024, Grünenthal employed around 4,300 people and achieved revenues of €1.8 billion.
More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group | Instagram: grunenthal
About BCWorldPharm
BCWorld Pharm Co., Ltd. is a KOSDAQ-listed South Korean specialty pharmaceutical company with a strong presence in the domestic pain market. The company is expanding its portfolio through global partnerships, including its recently expanded collaboration on Nucynta®. Under its Vision 2030 strategy, BCWorld Pharm aims to strengthen its leadership in specialty pain care in Korea and beyond.”
More information: www.bcwp.co.kr/eng/
Subscribe to releases from Grünenthal Group
Subscribe to all the latest releases from Grünenthal Group by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Grünenthal Group
Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development18.2.2026 12:17:07 EET | Press release
Aachen, Germany, 18 February 2026 – Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in the second half of 2026. The Phase I trial will involve 70 healthy volunteers and comprises a Single Ascending Dose and a Multiple Ascending Dose part. It aims to assess the safety and tolerability profile and the pharmacokinetic characteristics of the investigational medicine. In addition, the trial will generate initial insights into the compound’s pharmacology through a cold-pressor test. “Inhibition of NaV 1.8 offers an exciting opportunity to provide patients with urgently needed non-opioid pain therapies,” says Uli Brödl, Chief Scientific Officer, Grünenthal. “While we have seen the first medicine targeting
Grünenthal licenses exclusive Canadian rights to testosterone replacement therapy Nebido® to Apotex6.2.2026 08:21:37 EET | Press release
Aachen, Germany & Toronto, Canada, February 5, 2026 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to Nebido® (testosterone undecanoate), a long-acting injectable therapy indicated for the treatment of male hypogonadism (testosterone deficiency).[1] Under the agreement, Searchlight Pharma, Apotex's branded medicine division, will pursue marketing authorisation and will market and distribute the product in Canada upon regulatory approval. Grünenthal will receive an upfront payment, regulatory milestone payments, and a margin on the sales. This agreement deepens the existing partnership between Grünenthal and Apotex and strengthens their shared commitment to expanding Canadian patients' access to important therapies. "We are delighted to expand our partnership with Apotex
Grünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors4.9.2025 11:00:00 EEST | Press release
Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery systems. Through this collaboration, Grünenthal PRO will offer final assembly, packaging and labelling of Molly® autoinjector. Grünenthal PRO will expand its capacity for final assembly of SHL autoinjectors by installing additional assembly lines in its Origgio, Italy facility in 2026. These new pre-validated lines for Molly® 1.0 and 2.25 mL autoinjector platform will enhance speed-to-market for pharma and biotech companies, building on Grünenthal’s 10 year-experience in SHL autoinjector assembly services. In parallel, SHL customers will benefit from access to Grünenthal PRO’s established expertise and capacity in delivering high quality, reliable contract manufacturing services. “Speed-to-mar
Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia2.6.2025 11:49:26 EEST | Press release
Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability.
Maren Thurow starts as new Head Global Communications at Grünenthal20.5.2025 12:12:34 EEST | Press release
Aachen, Germany, 20th May 2025 - Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company’s Communications department since 2021. In her new position, Maren will oversee Grünenthal’s communications operations across all markets and lead the team based at the company’s headquarters in Aachen. She will report directly to CEO Gabriel Baertschi. This appointment comes at a pivotal moment in Grünenthal’s transformation, following the company’s outstanding financial performance in 2024. Since 2017, Grünenthal’s profitability, measured by adjusted EBITDA, has more than tripled, driven by strategic acquisitions and partnerships such as the acquisition of the US company Valinor Pharma and the product Movantik™ in July 2024. Additionally, Grünenthal continues to advance its key R&D programs, including progressing the Glucocorticoid Receptor Modulator (GRM) and Nocicept